Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Karen Xu, Karthik Ramesh, Vicki Huang, Saumya S. Gurbani, James Scott Cordova, Eduard Schreibmann, Brent D. Weinberg, Soma Sengupta, Alfredo D. Voloschin, Matthias Holdhoff, Peter B. Barker, Lawrence R. Kleinberg, Jeffrey J. Olson, Hui-Kuo G. Shu, Hyunsuk Shim
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2022-03-01
Serie:Tomography
Soggetti:
glioblastoma
histone deacetylase
epigenetic drug
radiation sensitizer
magnetic resonance spectroscopy
Accesso online:https://www.mdpi.com/2379-139X/8/2/57
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi